FMS Fresenius Medical Care AG
$22.37▲ +0.07%
Unknown
Other
Last sync: just now
Syncing
Key Metrics & Fundamentals
Market Cap
$12.01B
P/E Ratio
11.9
Div Yield
3.90%
52W Range
20.02 - 29.07
% vs 50 MA
0.51%
% vs 200 MA
-5.74%
RSI-14
55.2
MACD Histogram
+0.1000
Beta (1Y vs SPY)
0.47
Free Cash Flow
$36.82M
Gross Rev
$4.61B
Gross Profit
$1.18B
EBITDA
$894.44M
COGS
$3.43B
Operating Exp
$803.94M
Operating Income
$375.56M
EBIT
$375.56M
Pretax Income
$207.52M
Net Income
$117.53M
EPS (Diluted)
0.22
Price & Volume History
Volume (M)
Financial Overview - Income Statement
Quarterly
Mar 2026 (Quarterly)
Social Sentiment
Avg +0.46 · 5 posts
NewsDiscussionTHE RECKONING. Shiller PE ratio crossed 40.16 this week.
r/wallstreetbets · Dec 17, 2025
The discussion about near-zero cash reserves in the market combined with the FMS cash level information creates a bearish sentiment.
negative
-0.60
DDNewsTrade$FMS (Focus Graphite) Could Be the Next Breakout Stock with NUCLEAR/DEFENCE Grade Graphite 🚀
r/wallstreetbets · Aug 28, 2025
The post is highly enthusiastic about FMS and describes it as a 'breakout stock' with positive catalysts.
very_positive
+1.00
NewsDiscussionLockheed Martin just awarded 11.7 Billion dollar contract by US Navy
r/wallstreetbets · Dec 20, 2024
The contract includes FMS customers, suggesting potential revenue growth.
positive
+0.50
NewsDiscussionInvestors are so confident in stocks, they have a record low allocation to the safety of cash
r/wallstreetbets · Dec 18, 2024
The post highlights a contrarian signal based on low cash allocation, suggesting investor confidence and a bullish outlook.
positive
+0.80
Raytheon awarded 1.3 Billion Navy / DOD contract just now $RTX
r/stocks · Dec 2, 2024
The post details a significant contract for FMS, indicating continued business and revenue potential.
positive
+0.60
AI Analysis
Generated May 28, 3:54 AM
Company Overview
Fresenius Medical Care AG (FMS) is a global leader in providing products and services for individuals with chronic kidney failure. The company operates a vast network of dialysis clinics and manufactures a comprehensive range of dialysis machines, dialyzers, and related medical products, establishing a strong integrated position in the essential renal care market.
Bull Case
- Essential and Non-Discretionary Service: Dialysis is a life-sustaining treatment, ensuring stable and inelastic demand for FMS's services and products regardless of economic cycles.
- Demographic Tailwinds: The global aging population and rising prevalence of chronic diseases like diabetes and hypertension are driving a continuous increase in chronic kidney disease, guaranteeing long-term demand growth.
- Attractive Valuation: A P/E ratio of 11.3 suggests the stock may be undervalued relative to its stable business model and market leadership, potentially offering an attractive entry point.
- Market Leadership and Integrated Model: As a dominant player in the dialysis industry, FMS benefits from economies of scale, an extensive global network, and an integrated approach covering both products and services, creating significant barriers to entry.
Bear Case
- Regulatory and Reimbursement Risks: FMS operates in a highly regulated healthcare environment, making it vulnerable to changes in government reimbursement policies (e.g., Medicare in the US) which can directly impact profitability.
- Operational Headwinds: The company faces ongoing inflationary pressures on labor, supplies, and energy costs, which can compress margins despite stable demand for its services.
- Technological Disruption and Competition: While a leader, the potential for new, less invasive treatments, advanced home dialysis solutions, or aggressive competition could disrupt its clinic-centric model and market share.
- Negative Price Momentum: The stock is in a clear downtrend, trading significantly below its 52-week high and key moving averages, indicating persistent selling pressure and a lack of positive catalysts in the near term.
Recent Performance
FMS has experienced significant negative price action, currently trading 26.0% below its 52-week high and near the lower end of its 52-week range. The stock is below both its 50-day (-3.6%) and 200-day (-9.6%) moving averages, confirming a bearish trend. The RSI-14 of 44.7 suggests the stock is not yet oversold but indicates prevailing selling pressure, reinforcing the current downtrend.
AI-generated analysis is for informational purposes only and does not constitute financial advice.
Not Financial Advice.
All data, scores, charts, and analysis on this site are provided for informational and educational purposes only
and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
Always consult a qualified financial advisor before making any investment decisions.
See our Legal Notice for full details.